Comparison Overview

EMS

VS

Cipla

EMS

Rodovia Jorn. Francisco Aguirre Proenca, Hortolandia, SP, 13186-525, BR
Last Update: 2025-12-17
View Profile
Between 750 and 799
http://www.ems.com.br

EMS is the leading pharmaceutical company in Brazil. Established since 45 years and with 100% national capital, the company has two industrial plants strategically placed in São Bernardo do Campo and Hortolândia, in the state of São Paulo. With a work based on daring, simplicity, excellence and responsibility, the company reached the top of the ranking, but not by chance. The strength of the brand belongs on the constant investments in structure and research, in the continuous expansion of the products line and in the pioneer attitude. As the first Brazilian laboratory to export medicine products to Europe and to produce, in the country, medicine products in fractioned packing and generics, EMS is definitively reinventing the pharmaceutical market.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,325
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
1
View Profile

Cipla

Lower Parel, Ganpatrao Kadam Marg,, Mumbai, Maharashtra, IN, 400013
Last Update: 2025-12-17
Between 750 and 799
http://www.cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 49,702
Subsidiaries: 7
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/ems.jpeg
EMS
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
EMS
100%
Compliance Rate
0/4 Standards Verified
Cipla
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for EMS in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Cipla in 2025.

Incident History — EMS (X = Date, Y = Severity)

EMS cyber incidents detection timeline including parent company and subsidiaries

Incident History — Cipla (X = Date, Y = Severity)

Cipla cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/ems.jpeg
EMS
Incidents

Date Detected: 12/2017
Type:Ransomware
Motivation: Financial
Blog: Blog
https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
Incidents

No Incident

FAQ

Cipla company demonstrates a stronger AI Cybersecurity Score compared to EMS company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

EMS company has historically faced a number of disclosed cyber incidents, whereas Cipla company has not reported any.

In the current year, Cipla company and EMS company have not reported any cyber incidents.

EMS company has confirmed experiencing a ransomware attack, while Cipla company has not reported such incidents publicly.

Neither Cipla company nor EMS company has reported experiencing a data breach publicly.

Neither Cipla company nor EMS company has reported experiencing targeted cyberattacks publicly.

Neither EMS company nor Cipla company has reported experiencing or disclosing vulnerabilities publicly.

Neither EMS nor Cipla holds any compliance certifications.

Neither company holds any compliance certifications.

Cipla company has more subsidiaries worldwide compared to EMS company.

Cipla company employs more people globally than EMS company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither EMS nor Cipla holds SOC 2 Type 1 certification.

Neither EMS nor Cipla holds SOC 2 Type 2 certification.

Neither EMS nor Cipla holds ISO 27001 certification.

Neither EMS nor Cipla holds PCI DSS certification.

Neither EMS nor Cipla holds HIPAA certification.

Neither EMS nor Cipla holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
References
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References